- Home
- EYEN vs QLGN Comparison
EYEN vs QLGN Comparison
Compare EYEN & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EYEN
- QLGN
- Stock Information
- Founded
- EYEN 2014
- QLGN 1996
- Country
- EYEN United States
- QLGN United States
- Employees
- EYEN N/A
- QLGN N/A
- Industry
- EYEN Biotechnology: Pharmaceutical Preparations
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- EYEN Health Care
- QLGN Health Care
- Exchange
- EYEN Nasdaq
- QLGN Nasdaq
- Market Cap
- EYEN 2.0M
- QLGN 2.2M
- IPO Year
- EYEN 2018
- QLGN N/A
- Fundamental
- Price
- EYEN $1.09
- QLGN $3.48
- Analyst Decision
- EYEN Hold
- QLGN
- Analyst Count
- EYEN 4
- QLGN 0
- Target Price
- EYEN $2.00
- QLGN N/A
- AVG Volume (30 Days)
- EYEN 45.2K
- QLGN 158.4K
- Earning Date
- EYEN 04-15-2025
- QLGN 05-06-2025
- Dividend Yield
- EYEN N/A
- QLGN N/A
- EPS Growth
- EYEN N/A
- QLGN N/A
- EPS
- EYEN N/A
- QLGN N/A
- Revenue
- EYEN $57,336.00
- QLGN N/A
- Revenue This Year
- EYEN $7,680.45
- QLGN N/A
- Revenue Next Year
- EYEN $315.38
- QLGN N/A
- P/E Ratio
- EYEN N/A
- QLGN N/A
- Revenue Growth
- EYEN 1414.02
- QLGN N/A
- 52 Week Low
- EYEN $0.85
- QLGN $2.85
- 52 Week High
- EYEN $124.80
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- EYEN 39.27
- QLGN 52.85
- Support Level
- EYEN $1.02
- QLGN $3.10
- Resistance Level
- EYEN $1.18
- QLGN $4.40
- Average True Range (ATR)
- EYEN 0.09
- QLGN 0.40
- MACD
- EYEN 0.06
- QLGN 0.05
- Stochastic Oscillator
- EYEN 72.73
- QLGN 40.32
About EYEN Eyenovia Inc.
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.